This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seligson, D. B. Articles by Figlin, R. A. Search for Related Content PubMed PubMed Citation Articles by Seligson, D. B. Articles by Figlin, R. A.

Epithelial Cell Adhesion Molecule (KSA) Expression

Pathobiology and Its Role as an Independent Predictor of Survival in Renal Cell Carcinoma

Departments of ¹ Pathology and Laboratory Medicine, ² Urology, ³ Biostatistics in the School of Public Health, ⁴ Human Genetics and ⁵ Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, California

Purpose: Epithelial cell adhesion molecule (EpCAM) is a widely expressed adhesion molecule in epithelial cancers. The purpose of this study is to determine the protein expression patterns of EpCAM in renal cell carcinoma (RCC) using tissue arrays linked to a clinicopathological database to evaluate both its predictive power in patient stratification and its suitability as a potential target for immunotherapeutic treatment strategies.

Experimental Design: The University of California, Los Angeles kidney cancer tissue microarray contains specimens from 417 patients treated with nephrectomy. EpCAM protein expression in tumors and matched morphologically normal renal tissues was evaluated using anti-EpCAM immunohistochemistry. The resultant expression reactivity was correlated with clinicopathological variables.

Results: EpCAM is consistently expressed in the distal nephron on normal renal epithelium. Clear cell RCCs show minimal and infrequent EpCAM expression, whereas chromophobe and collecting duct RCCs both demonstrate intense and frequent expression. Of 318 clear cell carcinomas used in the analysis, 10% were EpCAM positive in 50% of cells, and 8% of patients would be considered candidates for EpCAM-based therapy, based on high expression [moderate intensity and frequent (50%) expression] and the need for systemic treatment. EpCAM expression was an independent prognostic factor for improved disease-specific survival, with a multivariate hazard ratio of 0.63 (P = 0.017; 95% confidence interval, 0.43–0.92).

Conclusions: EpCAM is a novel prognostic molecular marker in RCC patients, and its positive expression is an independent predictor associated with improved survival. However, high expression in morphologically normal renal tissues and minimal or absent expression in clear cell carcinomas will likely limit the utility of this epithelial marker in targeted treatments of this most common RCC type.

This article has been cited by other articles:

				T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 894 - 900. [Abstract] [Full Text] [PDF]

				T. Nubel, J. Preobraschenski, H. Tuncay, T. Weiss, S. Kuhn, M. Ladwein, L. Langbein, and M. Zoller Claudin-7 Regulates EpCAM-Mediated Functions in Tumor Progression Mol. Cancer Res., March 1, 2009; 7(3): 285 - 299. [Abstract] [Full Text] [PDF]

				T. Klatte, A. J. Pantuck, J. W. Said, D. B. Seligson, N. P. Rao, J. C. LaRochelle, B. Shuch, A. Zisman, F. F. Kabbinavar, and A. S. Belldegrun Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma Clin. Cancer Res., February 15, 2009; 15(4): 1162 - 1169. [Abstract] [Full Text] [PDF]

				A Brunner, M Prelog, I Verdorfer, A Tzankov, G Mikuz, and C Ensinger EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder J. Clin. Pathol., March 1, 2008; 61(3): 307 - 310. [Abstract] [Full Text] [PDF]

				M. Trzpis, P. M.J. McLaughlin, L. M.F.H. de Leij, and M. C. Harmsen Epithelial Cell Adhesion Molecule: More than a Carcinoma Marker and Adhesion Molecule Am. J. Pathol., August 1, 2007; 171(2): 386 - 395. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. J. Pantuck, A. S. Belldegrun, and R. A. Figlin Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials Clin. Cancer Res., January 15, 2007; 13(2): 703s - 708s. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575. [Abstract] [Full Text] [PDF]

				S. Krishnakumar, A. Mohan, K. Mallikarjuna, N. Venkatesan, J. Biswas, M. P. Shanmugam, and L. Ren-Heidenreich EpCAM Expression in Retinoblastoma: A Novel Molecular Target for Therapy Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4247 - 4250. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. S. Belldegrun, and R. A. Figlin Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy Clin. Cancer Res., September 15, 2004; 10(18): 6304S - 6309S. [Abstract] [Full Text] [PDF]